Results 51 to 60 of about 3,046 (215)

Mavacamten in Hypertrophic Cardiomyopathy: Getting Safety Right When the Buffer Is Small. [PDF]

JACC Asia
Zheng H.
europepmc   +2 more sources

Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide [PDF]

, 2023
BackgroundHypertrophic cardiomyopathy (HCM) is a genetic disorder for which first-line treatments for obstructive HCM (oHCM) include beta-blockers, non-dihydropyridine calcium channel blockers, and disopyramide for refractory cases.
Jorge Silva Enciso, Andrew Willeford, Enciso, Jorge Silva, Willeford, Andrew   +3 more
core   +1 more source

Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis

The Egyptian Heart Journal, 2023
Background Hypertrophic cardiomyopathy (HCM) is a hereditary myocardial disorder, often due to sarcomere gene mutations, characterized by the left ventricular hypertrophy. Current treatments offer symptomatic relief but lack specificity.
Hussain Sohail Rangwala, Hareer Fatima, Mirha Ali, Syed Taha Ahmed, Burhanuddin Sohail Rangwala, Syed Raza Abbas   +5 more
doaj   +1 more source

Effect of chronopharmacology and food on in vivo pharmacokinetic profile of mavacamten: supplementary materials

, 2023
Aim: This study investigated the impact of food intake and circadian rhythms on the pharmacokinetics of mavacamten. Materials & methods: A sensitive bioanalytical method for quantifying mavacamten in rat plasma was developed and validated. Thismethod was
Siva Nageswara Rao Gajula (15995481), Manoj P Dandekar (15995488), Ziaur Rahman (390962), Sasikala Talari (15995482), Rajesh Sonti (1831000), Vijay Munjal (15995485), Tanaaz Navin Nathani (15995483)   +6 more
core   +1 more source

MAVACAMTEN NO TRATAMENTO DA CARDIOMIOPATIA HIPERTRÓFICA [PDF]

, 2023
Introduction: Hypertrophic cardiomyopathy (HCM) is one of the most common genetic heart diseases, affecting between 0.16% and 0.29% of the general adult population.
Godinho de Freitas, Ana Clara, Peruzzi Iamaguti, Júlia, Barbosa Honorato, Taís, Pereira de Paiva, Caique, Tochihide Iamaguti, Felipe, Mendonça Rocha, Carollayne, Henrique Costa Pinto , Genon, Romaquela Rodrigues, Marina, Germinari Souza, Carla Lana, Ribeiro Moioli, Tagstan   +9 more
core   +1 more source

Is mavacamten superior to aficamten for hypertrophic cardiomyopathy? A frequentist network meta-analysis [PDF]

Exploration of Cardiology
Background: Myosin inhibitors have been shown to improve exercise capacity and symptoms, as well as reduce the left ventricular outflow tract (LVOT) gradient. This study explores the efficacy of mavacamten versus aficamten in hypertrophic cardiomyopathy (
Ayesha Aman, Bisma Akram, Arfa Akram, Momina Maham, Eisha Tariq, Aimen Hassan, Masooma Zainab Bokhari, Aleena Akram, Sania Akram, Malik Waleed Zeb Khan   +9 more
doaj   +1 more source

Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations [PDF]

, 2020
Thin filament hypertrophic cardiomyopathy (HCM) mutations increase myofilament Ca2+- sensitivity and alter Ca2+ handling and buffering. The myosin inhibitor mavacamten reverses the increased contractility caused by HCM thick filament mutations, and we ...
Redwood, Charles, Sparrow, Alexander J, Robinson, Paul, Daniels, Matthew J, Watkins, Hugh   +4 more
core   +1 more source

Mavacamten: A Novel Disease-Specific Treatment for Hypertrophic Cardiomyopathy

, 2023
Hypertrophic cardiomyopathy (HCM) is characterized by an abnormal thickening of the myocardium, leading to left ventricular outflow tract obstruction. Current treatments for HCM include non-disease-specific medications such as beta blockers or invasive ...
William H. Frishman, Capilupi, Michael J, Frishman, William H, Michael J. Capilupi   +3 more
core   +1 more source

Mavacamten for hypertrophic obstructive cardiomyopathy – Authors' reply [PDF]

The Lancet, 2021
reply to ...
Jacoby D., Ho C. Y., Lester S. J., Wang A., Olivotto I.   +4 more
openaire   +2 more sources

Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy

BMJ Open, 2023
Introduction Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease commonly caused by pathogenic genetic variants encoding sarcomere proteins.
Qing Zhang, Fang Wang, Yaling Han, Jing Sun, Shuyang Zhang, Wei Jin, Zhuang Tian, Ping Yang, Geng Wang, Jingmin Zhou, Peiwen Hsu   +10 more
doaj   +1 more source